Document is current
Any future updates will be listed below
-
Authors
Schuster, Anne LR https://orcid.org/0000-0003-4391-1712
Bollinger, Juli https://orcid.org/0000-0001-6850-8562
Geller, Gail
Little, Susan J. https://orcid.org/0000-0002-7645-9737
Mehta, Sanjay R.
Sanchez, Travis
Sugarman, Jeremy https://orcid.org/0000-0001-7022-8332
Bridges, John FP
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01MH124590)
John FP Bridges holds an Innovation in Regulatory Science Award from the Burroughs Wellcome Fund
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 10 October 2025
First Online: 14 November 2025
Competing interests
: J.S. is a consultant to Merck KGaA, IQVIA, and Merck; he is also a member of Aspen Neurosciences’ Clinical Advisory Panel. None of these activities is related to the material discussed in this article. SJL receives funding to her institution from Gilead Sciences unrelated to this research. None of these activities is related to the material discussed in this article. T.S. and J.F.P.B. have a research grant with ViiV Healthcare, but that research is not related to the material discussed in this article. A.L.R.S. receives funding to her institution from Pfizer unrelated to this research. None of the activities is related to the material discussed in this article. J.F.P.B. is a consultant to Boehringer Ingelheim. J.M.B., G.G., S.R.M. declare no competing interests.
